PL3216790T3 - Postać krystaliczna wodorosiarczanu inhibitora kinazy JAK i sposób jej otrzymywania - Google Patents

Postać krystaliczna wodorosiarczanu inhibitora kinazy JAK i sposób jej otrzymywania

Info

Publication number
PL3216790T3
PL3216790T3 PL15857844T PL15857844T PL3216790T3 PL 3216790 T3 PL3216790 T3 PL 3216790T3 PL 15857844 T PL15857844 T PL 15857844T PL 15857844 T PL15857844 T PL 15857844T PL 3216790 T3 PL3216790 T3 PL 3216790T3
Authority
PL
Poland
Prior art keywords
preparation
crystalline form
kinase inhibitor
jak kinase
bisulfate
Prior art date
Application number
PL15857844T
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Quanliang ZHANG
Yongjiang Chen
Lingjia SHEN
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of PL3216790T3 publication Critical patent/PL3216790T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PL15857844T 2014-11-05 2015-10-09 Postać krystaliczna wodorosiarczanu inhibitora kinazy JAK i sposób jej otrzymywania PL3216790T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410617808 2014-11-05
PCT/CN2015/091527 WO2016070697A1 (zh) 2014-11-05 2015-10-09 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
EP15857844.3A EP3216790B1 (en) 2014-11-05 2015-10-09 Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof

Publications (1)

Publication Number Publication Date
PL3216790T3 true PL3216790T3 (pl) 2020-05-18

Family

ID=55908546

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15857844T PL3216790T3 (pl) 2014-11-05 2015-10-09 Postać krystaliczna wodorosiarczanu inhibitora kinazy JAK i sposób jej otrzymywania

Country Status (20)

Country Link
US (1) US10023577B2 (pl)
EP (1) EP3216790B1 (pl)
JP (1) JP6851572B2 (pl)
KR (1) KR102522895B1 (pl)
CN (1) CN105980390B (pl)
AU (1) AU2015342444B2 (pl)
BR (1) BR112017007953B1 (pl)
CA (1) CA2965716C (pl)
CY (1) CY1122468T1 (pl)
DK (1) DK3216790T3 (pl)
ES (1) ES2754548T3 (pl)
HR (1) HRP20192030T1 (pl)
HU (1) HUE047404T2 (pl)
PL (1) PL3216790T3 (pl)
PT (1) PT3216790T (pl)
RS (1) RS59669B1 (pl)
RU (1) RU2716260C2 (pl)
SI (1) SI3216790T1 (pl)
TW (1) TWI672305B (pl)
WO (1) WO2016070697A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786507B2 (en) 2016-02-19 2020-09-29 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
TW201827436A (zh) * 2017-01-20 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
AU2021318201A1 (en) 2020-07-28 2023-02-02 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
WO2022108913A1 (en) 2020-11-17 2022-05-27 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74370C2 (uk) * 2000-06-26 2005-12-15 Пфайзер Продактс Інк. Піроло(2,3-d)піримідинові сполуки як імуносупресори
MXPA05010712A (es) * 2003-04-04 2005-12-15 Novartis Ag Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
JP5227032B2 (ja) * 2005-02-03 2013-07-03 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロピリミジン
WO2012171863A1 (en) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
US9527851B2 (en) * 2011-12-21 2016-12-27 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
US9422300B2 (en) * 2013-06-07 2016-08-23 Jiangsu Hengrui Medicine Co., Ltd. Bisulfate of janus kinase (JAK) inhibitor and preparation method therefor
CN105566327A (zh) 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法

Also Published As

Publication number Publication date
BR112017007953B1 (pt) 2023-12-05
RU2716260C2 (ru) 2020-03-11
EP3216790A4 (en) 2018-04-25
BR112017007953A2 (pt) 2017-12-19
AU2015342444A1 (en) 2017-05-18
PT3216790T (pt) 2019-11-19
ES2754548T3 (es) 2020-04-20
US20170313709A1 (en) 2017-11-02
US10023577B2 (en) 2018-07-17
WO2016070697A1 (zh) 2016-05-12
CY1122468T1 (el) 2021-01-27
AU2015342444B2 (en) 2019-12-12
CA2965716A1 (en) 2016-05-12
EP3216790A1 (en) 2017-09-13
TW201617347A (zh) 2016-05-16
KR102522895B1 (ko) 2023-04-17
EP3216790B1 (en) 2019-10-02
HUE047404T2 (hu) 2020-04-28
CN105980390B (zh) 2017-07-07
SI3216790T1 (sl) 2020-02-28
TWI672305B (zh) 2019-09-21
CN105980390A (zh) 2016-09-28
RU2017118193A (ru) 2018-12-05
JP6851572B2 (ja) 2021-03-31
HRP20192030T1 (hr) 2020-02-07
KR20170078710A (ko) 2017-07-07
JP2017532327A (ja) 2017-11-02
RU2017118193A3 (pl) 2019-05-08
CA2965716C (en) 2023-03-21
DK3216790T3 (da) 2019-11-25
RS59669B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
HK1243419B (zh) 一種btk激酶抑制劑的結晶形式及其製備方法
SG11201610771SA (en) Method of manufacturing a substrate
PL3206816T3 (pl) Sposób wytwarzania elementu składowego i element składowy
HK1206026A1 (zh) 種 激酶抑制劑的硫酸氫鹽及其製備方法
HUE052924T2 (hu) A JAK gátló biszulfátjának kristályos formája és annak elõkészítési eljárása
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL254530A0 (en) Preparation method of crystalline form a of pci-32765
HK1244274A1 (zh) C21h22ci2n4o2的晶型
PL3216790T3 (pl) Postać krystaliczna wodorosiarczanu inhibitora kinazy JAK i sposób jej otrzymywania
IL253186B (en) A new crystalline form of a benzaimidazole derivative and a method for its preparation
SI3327012T1 (sl) Kristalinične oblike bilastina in postopki za pripravo le-teh
IL253479A0 (en) Crystalline forms of efinconazole
PT3113773T (pt) Formas cristalinas do grapiprant
PL3183173T3 (pl) Opakowanie i sposób jego wytwarzania
GB201506484D0 (en) A method of sintering
EP3341169C0 (en) METHOD FOR FORMING A CERAMIC PRODUCT
ZA201606570B (en) A method of forming concrete
LT2937159T (lt) Veržliarakčio gamybos būdas
EP3362420C0 (en) METHOD FOR PRODUCING A CERAMIC PRODUCT
IL239014A (en) A method for making tefillin and the tefillin is manufactured
SG11201608466XA (en) Perforated substrate and a method of manufacture
GB201515305D0 (en) Method of preventing a fall
SG10201401365VA (en) Perforated substrate and a method of manufacture